Can IBD be predicted and possibly prevented?
IBDGastroent Hepatol 2022; 76(3): 264–267.
SummaryLiteraturepdf Ondřej HradskýRecommendation for Vaccinations in Patients with Crohn
IBDČes a Slov Gastroent a Hepatol 2010; 64(1): 40-48 .
Summarypdf Jiří Stehlík, Karel Mareš, Milan Lukáš, Martin Bortlík, Dana ĎuricováResults of prospective evaluation of mucosal changes in the small bowel by capsule enteroscopy in patients with Crohn´s disease treated with infliximab and adalimumab
IBDČes a Slov Gastroent a Hepatol 2010; 64(2): 22-30.
Summarypdf Ladislav Kužela, Marián Oltman, Jarolím Šutka, Barbora Zacharová, Peter Paulen, Beáta Repáková, Vladimír Syč-Milý, Miroslava Rajská5. ECCO kongres, Kongresové centrum v Praze, 25.-27.2.2010
IBDČes a Slov Gastroent a Hepatol 2010; 64(2): 31-36.
pdf Milan Lukáš, Martin BortlíkRifaximin in the treatment of Crohn´s disease. Results of the GRACE 02 study
IBDČes a Slov Gastroent a Hepatol 2010; 64(3): 31-36.
Summarypdf Dana Ďuricová, Martin Bortlík, Milan LukášThe efficacy of maintenance therapy in ulcerative colitis is influenced by the pharmacokinetics of mesalazine and by adherence to medicamentous therapy Commentary to the PODIUM study
IBDČes a Slov Gastroent a Hepatol 2010; 64(5): 26-29.
Summarypdf Milan LukášFertility, pregnancy, breastfeeding and chronic inflammatory bowel diseases - Consensus of the ECCO 2010
IBDČes a Slov Gastroent a Hepatol 2010; 64(6): 26-30.
Summarypdf Marián BátovskýCrucial questions and answers regarding Crohn's disease therapy Conclusions of the international IBD-AHEAD project
IBDČes a Slov Gastroent a Hepatol 2010; 64(6): 21-25.
Summarypdf Milan Lukáš